Image de couverture de livre

Prognostic Nutritional Index as a Biomarker in Metastatic Hormone‐Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Muhammet Bekir Hacioglu, Ahmet Kucukarda, Ivo Gokmen, Ali Fuat Gurbuz, Murat Araz, Fatma Akdag Kahvecioglu, Ilhan Hacibekiroglu, Orhun Akdoğan, Ozan Yazıcı, Fatma Aysun Akkus, Abdussamet Çelebi, Osman Kostek, Bulent Erdogan
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	The Prostate
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Bone Metastasis Distribution Matters: Prognostic Effect of the Axial‐to‐Peripheral Ratio in Metastatic Hormone‐Sensitive Prostate Cancer
par: Ali Fuat Gürbüz, et autres
Publié: (2026)

Role of Volumetric Parameters Derived From Ga‐68 PSMA PET‐CT in Predicting Treatment Response
par: Ali Uyar, et autres
Publié: (2025)

Nomograms for detecting lymph node metastasis detected with surgery—Can you name any birds other than crow?
par: Cem Onal, et autres
Publié: (2024)

The effect of dose‐escalation radiotherapy with simultaneous‐integrated‐boost on the use of short‐term androgen deprivation therapy in patients with intermediate risk prostate cancer
par: Cem Onal, et autres
Publié: (2024)

Propensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate Cancer
par: Cem Onal, et autres
Publié: (2025)

Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy
par: Cem Onal, et autres
Publié: (2026)

Is Cystolitholapaxy Sufficient in Patients With Bladder Stones Secondary to Benign Prostatic Obstruction?
par: Mert Hamza Özbilen, et autres
Publié: (2026)

Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients
par: Cem Onal, et autres
Publié: (2024)

Impact of definitive radiotherapy on metabolic response measured with 68Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer
par: Cem Onal, et autres
Publié: (2024)

PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
par: Philip Sutera, et autres
Publié: (2024)

Other‐cause mortality in incidental prostate cancer
par: Francesco Di Bello, et autres
Publié: (2024)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
par: Takanori Tokunaga, et autres
Publié: (2025)

Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy
par: Yuto Ono, et autres
Publié: (2025)

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer
par: Cevat İlteriş Kıkılı, et autres
Publié: (2026)

Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors
par: Hyun‐Kyung Ko, et autres
Publié: (2025)

Cover Image: Volume 86 Issue 7
par: Amod Sharma, et autres
Publié: (2026)

External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high‐grade prostate cancer patients
par: Nawar Touma, et autres
Publié: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
par: Eric V. Li, et autres
Publié: (2024)

Discovering the Prostate: Notes on History and Historiography
par: Diederik F. Janssen
Publié: (2025)

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System
par: Toshifumi Takahashi, et autres
Publié: (2024)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
par: Fabian Falkenbach, et autres
Publié: (2025)

Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists
par: Satı Coşkun Yazgan, et autres
Publié: (2026)

Real‐World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Propensity‐Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis
par: Yosuke Yasuda, et autres
Publié: (2026)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
par: Mark Kidd, et autres
Publié: (2025)

Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
par: Meryam Losee, et autres
Publié: (2025)

Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer
par: Hirotaka Nagasaka, et autres
Publié: (2024)

Individualized Precision Prostate Biopsy Strategy for Patients With PI‐RADS Score 2: A Retrospective Multicenter Study
par: Zhiyao Xu, et autres
Publié: (2025)

Integration of Primary Care Into the Follow‐Up Protocol for Prostate Cancer Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the Region
par: Angel Borque‐Fernando, et autres
Publié: (2025)

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
par: Christian P. Pavlovich, et autres
Publié: (2025)

Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro
par: Megan H. Check, et autres
Publié: (2025)

Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization
par: Pedro Ivo C. Ravizzini, et autres
Publié: (2026)

Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
par: Umang Swami, et autres
Publié: (2024)

Correction to “[Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study ( The Prostate , 2025). https://doi.org/10.1002/pros.70071]”
Publié: (2026)

Robotic‐Assisted Radical Prostatectomy in the Elderly Patient—A Study of Functional, Surgical, and Oncological Outcomes in an Australian Cohort
par: Victor Yu, et autres
Publié: (2025)

Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
par: Shintaro Narita, et autres
Publié: (2024)

Spatial Distribution of Prostate Cancer Missed by MRI‐Targeted Biopsy, Effect of a Perilesional Template, and Restaging in a Radical Prostatectomy Cohort
par: Ruth Himmelsbach, et autres
Publié: (2026)

Letter to the Editor Regarding “Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization”
par: Eriz Özden, et autres
Publié: (2026)

Ten‐year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot‐assisted radical prostatectomy
par: Enrico Checcucci, et autres
Publié: (2024)

Issue Information
Publié: (2024)

Overall and metastasis‐free survival of Afro‐Caribbean patients with biochemical recurrence after radical prostatectomy
par: Hugo Barriere, et autres
Publié: (2024)